Meda Sues Perrigo, Impax Over Generic Nasal Spray

Law360, New York (February 27, 2014, 3:29 PM EST) -- Meda Pharmaceuticals Inc. sued Perrigo Co. and Impax Laboratories Inc. on Wednesday, saying the generic-drug makers' plan to market and sell their own version of Meda's antihistamine spray Astepro would infringe the company's patent.

Meda alleged in a complaint filed in federal court in New Jersey that Perrigo and Impax's abbreviated new drug application would violate a patent for Astepro, U.S. Patent Number 8,518,919, titled, "Compositions comprising azelastine and methods of use thereof." The U.S. Patent and Trademark Office issued the patent on Aug. 27, 2013. ...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.